トップページ

2021.09.13

MediciNova is a biopharmaceutical company that is developing
novel therapeutics with a primary focus on neurology, respiratory,
and liver diseases with unmet medical needs.

MediciNova is a biopharmaceutical company that is developing
novel therapeutics with a primary focus on neurology, respiratory,
and liver diseases with unmet medical needs.

Press release

2026/04/27

New Peer‑Reviewed Study Reveals Actionable Immune–Microenvironment Target in Brain Metastasis; Medicinova Advances Clinical Translation
2026/03/16

MediciNova to Participate at the 38th Annual ROTH Conference
2026/01/29

MediciNova Announces 100 Patients Enrolled in SEANOBI Study Expanded-Access-Program (EAP) Evaluating MN‑166 (ibudilast) in ALS patients
2026/01/06

2026 New Year’s Greetings from the CEO
2025/12/18

MediciNova Announces Completion of Patient Enrollment Evaluating MN-166 (ibudilast) in the Prevention of Chemotherapy-induced Peripheral Neuropathy
2025/12/08

MediciNova Announces Update and Basic Characteristic Randomized Patients’ of Phase 2/3 Clinical Trial of MN-166 (Ibudilast) in ALS (COMBAT-ALS Clinical Trial) Presented at the 36th International Symposium on ALS/MND
Press release More Info
2026/04/27

New Peer‑Reviewed Study Reveals Actionable Immune–Microenvironment Target in Brain Metastasis; Medicinova Advances Clinical Translation
2026/03/16

MediciNova to Participate at the 38th Annual ROTH Conference
2026/01/29

MediciNova Announces 100 Patients Enrolled in SEANOBI Study Expanded-Access-Program (EAP) Evaluating MN‑166 (ibudilast) in ALS patients
2026/01/06

2026 New Year’s Greetings from the CEO
2025/12/18

MediciNova Announces Completion of Patient Enrollment Evaluating MN-166 (ibudilast) in the Prevention of Chemotherapy-induced Peripheral Neuropathy
2025/12/08

MediciNova Announces Update and Basic Characteristic Randomized Patients’ of Phase 2/3 Clinical Trial of MN-166 (Ibudilast) in ALS (COMBAT-ALS Clinical Trial) Presented at the 36th International Symposium on ALS/MND
Press release More Info



Page Top